Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of perphenazine in preparing medicament for treating endometrial carcinoma

A technology of endometrial cancer and perphenazine, which is applied in the field of drug therapy to achieve the effects of inhibiting growth, inducing apoptosis, and inhibiting phosphorylation

Pending Publication Date: 2020-06-26
EAST CHINA UNIV OF SCI & TECH +1
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Perphenazine is a drug used clinically to treat mental illness, and there is no literature report that perphenazine can be used to treat endometrial cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of perphenazine in preparing medicament for treating endometrial carcinoma
  • Application of perphenazine in preparing medicament for treating endometrial carcinoma
  • Application of perphenazine in preparing medicament for treating endometrial carcinoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Proliferation inhibitory effect of perphenazine on endometrial cancer cells Ishikawa (ISK, type I, progesterone-sensitive), KLE cells (type II, progesterone-resistant), HEC-1A, HEC-1B and AR3CAN

[0033] 1. Experimental materials and methods

[0034] Endometrial cancer cells ISK, KLE, HEC-1A, HEC-1B and AR3CAN were purchased from the American Type Culture Collection (ATCC); phosphate buffered saline (PBS), DME / F12 medium were purchased from Hyclone; Serum (FBS) was purchased from Gibco; pancreatin and CCK8 were purchased from Beyontian Biotechnology Co., Ltd.; perphenazine (PPZ) and medroxyprogesterone acetate (MPA) were from the old drug library of the laboratory. The specific experimental method is as follows:

[0035] 1) Take the cells in the logarithmic growth phase, pour off the culture medium in the culture dish, and add 2 mL of PBS to wash the cells twice.

[0036] 2) Add 1 mL of trypsin and digest at room temperature for 2 min.

[0037] 3) Add 2 mL of culture...

Embodiment 2

[0049] Effects of perphenazine and MPA on the colony formation of Ishikawa and KLE cells

[0050] 1. Experimental materials and methods

[0051] Crystal violet was purchased from Biyuntian Biotechnology Co., Ltd.; methanol is a commonly used reagent in the laboratory, purchased commercially, without any treatment. All the other experimental materials are from the same sources as in Example 1. The specific experimental method is as follows:

[0052] 1) Take the cells in the logarithmic growth phase, digest them with trypsin to prepare a single-cell suspension, serially dilute, inoculate into a 6-well plate at a density of about 800 cells per well, and wait overnight for them to adhere to the wall.

[0053] 2) Five experimental groups were established, which were control group; MPA 20 μM group; MPA 30 μM group; PPZ 20 μM group; PPZ 30 μM group. The drug-administered group was cultured with 1 mL of DME / F12 medium containing different concentrations of drugs for 2 days, and the...

Embodiment 3

[0062] Effects of perphenazine and MPA on the migration ability of Ishikawa and KLE cells

[0063] 1. Experimental materials and methods

[0064] Paraformaldehyde is a commonly used reagent in the laboratory, commercially purchased without any treatment, and the sources of the rest of the experimental materials are the same as in Example 1. The specific experimental methods are as follows:

[0065] 1) Take 100 μL (about 200,000 cells) of serum-free ISK / KLE cell suspension and add it to the upper chamber of the Transwell chamber. The medium used for the cell suspension is serum-free DME / F12 medium.

[0066] 2) Add 600 μL of DME / F12 medium containing 20% ​​FBS to the lower chamber, taking care to avoid the generation of air bubbles.

[0067] 3) Three experimental groups were established, which were control group; MPA 10 μM group; PPZ 10 μM group. 100 μL of serum-free DME / F12 medium containing different drugs was added to the upper chamber of the administration group. Add 100...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of perphenazine in preparing a medicament for treating endometrial carcinoma, wherein the endometrial carcinoma comprises type I endometrial carcinoma and type II endometrial carcinoma. Experiments show that perphenazine has an inhibition effect on proliferation, clone formation and migration capacity of Ishikawa and KLE cells of endometrial carcinoma, can induce cell apoptosis, inhibit cell AKT phosphorylation and inhibit growth of mouse subcutaneous transplantation tumor, and is proved to be effective in mouse experiments. Accordingly, the invention provides the new application of the antipsychotic drug perphenazine for treatment of endometrial cancer.

Description

technical field [0001] The invention belongs to the technical field of pharmacotherapeutics, and in particular relates to the application of perphenazine in the preparation of medicines for treating endometrial cancer. Background technique [0002] Endometrial cancer (EC) is one of the malignant tumors of the female reproductive tract worldwide, and its incidence is increasing (Morice, The Lancet, 2016, 387, 1094–108), and up to 25% of women are Premenopausal onset (Sanderson, Obstetrics, Gynaecology & Reproductive Medicine, 2019, 29, 225-232). According to the report of the American Cancer Society, in 2020, the United States is expected to have 65,620 new EC cases and 12,590 new EC deaths (Siegel, CA: A Cancer Journal for Clinicians, 2020, 70, 7-30). In 2015, there were about 63,400 new EC cases and about 21,800 new EC deaths in China (Chen, CA: A Cancer Journal for Clinicians, 2016, 66, 115-132). In recent years, the age of onset of EC in China has also tended to be youn...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/5415A61P35/00A61P35/04
CPCA61K31/5415A61P35/00A61P35/04
Inventor 毛斐王玉东陈洋孙笑崔云霞朱进伍慧雯李杨王柄巽李晓康李剑
Owner EAST CHINA UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com